miR-200a | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

5,873 results for “miR-200a”

University of Iowa Develops Gene Therapy to Prevent Craniosynostosis in Newborns

CSF Biomarkers NfL, CHIT1, and miR-181b Evaluated for ALS Diagnosis and Prognosis

Australian researchers uncover molecular switch driving triple-negative breast cancer metastasis, pointing to CDK4/6 inhibitor repurposing

HDAC Inhibition in Muscle Cells Enhances Bone Regeneration via Extracellular Vesicles

Sanofi Invests in Resalis Therapeutics' miRNA-22 Inhibitor for Obesity Treatment

Novel miRNA-129–Based Therapy Achieves Over 95% Tumor Shrinkage in Preclinical NSCLC Model, Halting Drug Resistance

NeuroSense's PrimeC Shows 33% Reduction in ALS Disease Progression in Phase 2b Trial

ARTHEx Biotech Secures $87M Series B to Advance Novel RNA Therapy for Myotonic Dystrophy Type 1

ARTHEx Biotech Receives FDA Fast Track Designation for ATX-01 in Myotonic Dystrophy Type 1

Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC Through GSK-3 Inhibition

Page 1 of 52